Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Checkpoint Therapeutics Inc (CKPT)
NASDAQ:CKPT
RESEARCH TOOLSreports
Checkpoint Therapeutics (CKPT) Stock Price & Analysis
1,755 Followers
CKPT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.30 - $3.62
Previous Close$1.44
Volume183.92K
Average Volume (3M)478.72K
Market Cap
$51.21M
Enterprise Value$49.44M
Total Cash (Recent Filing)$1.77M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)-0.5
Beta1.16
Next Earnings
May 09, 2024EPS Estimate
-$0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.93
Shares Outstanding35,686,279
10 Day Avg. Volume421,625
30 Day Avg. Volume478,716
Standard Deviation0.20
R-Squared0.07
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)-3.97
Price to Sales (P/S)261.49
Price to Cash Flow (P/CF)-1.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue289.11
Enterprise Value/Gross Profit257.49
Enterprise Value/Ebitda-1.00
Forecast
1Y Price Target
$34.00Price Target Upside2261.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Checkpoint Therapeutics News
PremiumCompany Announcements
Checkpoint Therapeutics Enhances Board with New Independent Director
PremiumCompany Announcements
Checkpoint Therapeutics Faces Nasdaq Compliance ChallengeBulls Say, Bears Say
Bulls Say
Financial PerformanceThe company's earnings per share for the recent quarter outperformed analyst and consensus estimates, indicating robust financial health and potential for future growth.
Market PotentialAnalysts recognize cosibelimab as a differentiated CKI therapy with significant market potential, underscoring its promise in the competitive cancer immunotherapy space.
Regulatory UpdateThe FDA's recent issuance of a CRL for cosibelimab highlighted no concerns about the clinical data, safety, or labeling, suggesting a solid foundation for its eventual approval.
Bears Say
Approval TimelineFollowing the resolution of issues outlined in the CRL, the Prescription Drug User Fee Act (PDUFA) date for cosibelimab will be determined, potentially extending the approval timeline further.
Market EntryThe CRL from the FDA will postpone the U.S. commercial launch of cosibelimab, as CKPT will need to address the issues and resubmit their application.
Regulatory ApprovalThe issuance of a Complete Response Letter (CRL) by the FDA for cosibelimab represents a significant delay in the regulatory approval process.
---
Ownership Overview
8.01% Insiders
2.01% Mutual Funds
3.13% Other Institutional Investors
86.85% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CKPT FAQ
What was Checkpoint Therapeutics Inc’s price range in the past 12 months?
Checkpoint Therapeutics Inc lowest stock price was $1.30 and its highest was $3.62 in the past 12 months.
What is Checkpoint Therapeutics Inc’s market cap?
Currently, no data Available
When is Checkpoint Therapeutics Inc’s upcoming earnings report date?
Checkpoint Therapeutics Inc’s upcoming earnings report date is May 09, 2024 which is in 14 days.
How were Checkpoint Therapeutics Inc’s earnings last quarter?
Checkpoint Therapeutics Inc released its earnings results on Mar 22, 2024. The company reported -$0.94 earnings per share for the quarter, missing the consensus estimate of -$0.575 by -$0.365.
Is Checkpoint Therapeutics Inc overvalued?
According to Wall Street analysts Checkpoint Therapeutics Inc’s price is currently Undervalued.
Does Checkpoint Therapeutics Inc pay dividends?
Checkpoint Therapeutics Inc does not currently pay dividends.
What is Checkpoint Therapeutics Inc’s EPS estimate?
Checkpoint Therapeutics Inc’s EPS estimate is -$0.27.
How many shares outstanding does Checkpoint Therapeutics Inc have?
Checkpoint Therapeutics Inc has 34,986,280 shares outstanding.
What happened to Checkpoint Therapeutics Inc’s price movement after its last earnings report?
Checkpoint Therapeutics Inc reported an EPS of -$0.94 in its last earnings report, missing expectations of -$0.575. Following the earnings report the stock price went up 2.105%.
Which hedge fund is a major shareholder of Checkpoint Therapeutics Inc?
Among the largest hedge funds holding Checkpoint Therapeutics Inc’s share is Fisher Asset Management LLC. It holds Checkpoint Therapeutics Inc’s shares valued at N/A.
---
Checkpoint Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$34.00 (2261.11% Upside)
$34.00 (2261.11% Upside)
Blogger Sentiment
Bullish
CKPT Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $48.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 9.1%
Last 30 Days ▼ 9.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-54.29%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-59.53%
Trailing 12-Months
Company Description
Checkpoint Therapeutics Inc
Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Its product portfolio include CK-301, CK-101, CK-103, and CK-302. The company was founded on November 10, 2014 and is headquartered in New York, NY.
---
CKPT Stock 12 Months Forecast
Average Price Target
$34.00
▲(2261.11% Upside)
Technical Analysis
Corvus Pharmaceuticals
―
Aileron Therapeutics
―
Assertio Therapeutics
―
AIM ImmunoTech
―
Best Analysts Covering CKPT
1 Year
1 Year Success Rate
2/10 ratings generated profit
1 Year Average Return
-20.60%
reiterated a buy rating 4 months ago
Copying Thomas Flaten's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -20.60% per trade.
---